Silencing of Long Noncoding RNA MIR22HG Triggers Cell Survival/Death Signaling via Oncogenes YBX1, MET, and p21 in Lung Cancer
Wenmei Su, Shumei Feng, Xiuyuan Chen, Xia Yang, Rui Mao, Chunfang Guo, Zhuwen Wang, Dafydd G. Thomas, Jules Lin, Rishindra M. Reddy, Mark B. Orringer, Andrew C. Chang, Zhixiong Yang, David G. Beer, Guoan Chen
The American Association for Cancer Research (AACR)
Published 2018
The American Association for Cancer Research (AACR)
Published 2018
| Publication Date: |
2018-06-16
|
|---|---|
| Publisher: |
The American Association for Cancer Research (AACR)
|
| Print ISSN: |
0008-5472
|
| Electronic ISSN: |
1538-7445
|
| Topics: |
Medicine
|
| Published by: |
| _version_ | 1836398972881600512 |
|---|---|
| autor | Wenmei Su, Shumei Feng, Xiuyuan Chen, Xia Yang, Rui Mao, Chunfang Guo, Zhuwen Wang, Dafydd G. Thomas, Jules Lin, Rishindra M. Reddy, Mark B. Orringer, Andrew C. Chang, Zhixiong Yang, David G. Beer, Guoan Chen |
| beschreibung | The long noncoding RNA (lncRNA) MIR22HG has previously been identified as a prognostic marker in hepatocellular carcinoma. Here, we performed a comprehensive analysis of lncRNA expression profiles from RNA-Seq data and report that MIR22HG plays a similar role in lung cancer. Analysis of 918 lung cancer and normal lung tissues and lung cancer cell lines revealed that MIR22HG was significantly downregulated in lung cancer; this decreased expression was associated with poor patient survival. MIR22HG bound and stabilized the YBX1 protein. Silencing of MIR22HG triggered both cell survival and cell death signaling through dysregulation of the oncogenes YBX1, MET, and p21. In this MIR22HG network, p21 played an oncogenic role by promoting cell proliferation and antiapoptosis in lung cancers. MIR22HG played a tumor-suppressive role as indicated by inhibition of multiple cell cycle–related genes in human primary lung tumors. These data show that MIR22HG has potential as a new diagnostic and prognostic marker and as a therapeutic target for lung cancer.Significance: The lncRNA MIR22HG functions as a tumor suppressor, with potential use a diagnostic/prognostic marker and therapeutic target in lung cancer. Cancer Res; 78(12); 3207–19. ©2018 AACR. |
| citation_standardnr | 6284360 |
| datenlieferant | ipn_articles |
| feed_id | 9360 |
| feed_publisher | The American Association for Cancer Research (AACR) |
| feed_publisher_url | http://www.aacr.org/ |
| insertion_date | 2018-06-16 |
| journaleissn | 1538-7445 |
| journalissn | 0008-5472 |
| publikationsjahr_anzeige | 2018 |
| publikationsjahr_facette | 2018 |
| publikationsjahr_intervall | 7984:2015-2019 |
| publikationsjahr_sort | 2018 |
| publisher | The American Association for Cancer Research (AACR) |
| quelle | Cancer Research |
| relation | http://cancerres.aacrjournals.org/content/78/12/3207.short?rss=1 |
| search_space | articles |
| shingle_author_1 | Wenmei Su, Shumei Feng, Xiuyuan Chen, Xia Yang, Rui Mao, Chunfang Guo, Zhuwen Wang, Dafydd G. Thomas, Jules Lin, Rishindra M. Reddy, Mark B. Orringer, Andrew C. Chang, Zhixiong Yang, David G. Beer, Guoan Chen |
| shingle_author_2 | Wenmei Su, Shumei Feng, Xiuyuan Chen, Xia Yang, Rui Mao, Chunfang Guo, Zhuwen Wang, Dafydd G. Thomas, Jules Lin, Rishindra M. Reddy, Mark B. Orringer, Andrew C. Chang, Zhixiong Yang, David G. Beer, Guoan Chen |
| shingle_author_3 | Wenmei Su, Shumei Feng, Xiuyuan Chen, Xia Yang, Rui Mao, Chunfang Guo, Zhuwen Wang, Dafydd G. Thomas, Jules Lin, Rishindra M. Reddy, Mark B. Orringer, Andrew C. Chang, Zhixiong Yang, David G. Beer, Guoan Chen |
| shingle_author_4 | Wenmei Su, Shumei Feng, Xiuyuan Chen, Xia Yang, Rui Mao, Chunfang Guo, Zhuwen Wang, Dafydd G. Thomas, Jules Lin, Rishindra M. Reddy, Mark B. Orringer, Andrew C. Chang, Zhixiong Yang, David G. Beer, Guoan Chen |
| shingle_catch_all_1 | Silencing of Long Noncoding RNA MIR22HG Triggers Cell Survival/Death Signaling via Oncogenes YBX1, MET, and p21 in Lung Cancer The long noncoding RNA (lncRNA) MIR22HG has previously been identified as a prognostic marker in hepatocellular carcinoma. Here, we performed a comprehensive analysis of lncRNA expression profiles from RNA-Seq data and report that MIR22HG plays a similar role in lung cancer. Analysis of 918 lung cancer and normal lung tissues and lung cancer cell lines revealed that MIR22HG was significantly downregulated in lung cancer; this decreased expression was associated with poor patient survival. MIR22HG bound and stabilized the YBX1 protein. Silencing of MIR22HG triggered both cell survival and cell death signaling through dysregulation of the oncogenes YBX1, MET, and p21. In this MIR22HG network, p21 played an oncogenic role by promoting cell proliferation and antiapoptosis in lung cancers. MIR22HG played a tumor-suppressive role as indicated by inhibition of multiple cell cycle–related genes in human primary lung tumors. These data show that MIR22HG has potential as a new diagnostic and prognostic marker and as a therapeutic target for lung cancer.Significance: The lncRNA MIR22HG functions as a tumor suppressor, with potential use a diagnostic/prognostic marker and therapeutic target in lung cancer. Cancer Res; 78(12); 3207–19. ©2018 AACR. Wenmei Su, Shumei Feng, Xiuyuan Chen, Xia Yang, Rui Mao, Chunfang Guo, Zhuwen Wang, Dafydd G. Thomas, Jules Lin, Rishindra M. Reddy, Mark B. Orringer, Andrew C. Chang, Zhixiong Yang, David G. Beer, Guoan Chen The American Association for Cancer Research (AACR) 0008-5472 00085472 1538-7445 15387445 |
| shingle_catch_all_2 | Silencing of Long Noncoding RNA MIR22HG Triggers Cell Survival/Death Signaling via Oncogenes YBX1, MET, and p21 in Lung Cancer The long noncoding RNA (lncRNA) MIR22HG has previously been identified as a prognostic marker in hepatocellular carcinoma. Here, we performed a comprehensive analysis of lncRNA expression profiles from RNA-Seq data and report that MIR22HG plays a similar role in lung cancer. Analysis of 918 lung cancer and normal lung tissues and lung cancer cell lines revealed that MIR22HG was significantly downregulated in lung cancer; this decreased expression was associated with poor patient survival. MIR22HG bound and stabilized the YBX1 protein. Silencing of MIR22HG triggered both cell survival and cell death signaling through dysregulation of the oncogenes YBX1, MET, and p21. In this MIR22HG network, p21 played an oncogenic role by promoting cell proliferation and antiapoptosis in lung cancers. MIR22HG played a tumor-suppressive role as indicated by inhibition of multiple cell cycle–related genes in human primary lung tumors. These data show that MIR22HG has potential as a new diagnostic and prognostic marker and as a therapeutic target for lung cancer.Significance: The lncRNA MIR22HG functions as a tumor suppressor, with potential use a diagnostic/prognostic marker and therapeutic target in lung cancer. Cancer Res; 78(12); 3207–19. ©2018 AACR. Wenmei Su, Shumei Feng, Xiuyuan Chen, Xia Yang, Rui Mao, Chunfang Guo, Zhuwen Wang, Dafydd G. Thomas, Jules Lin, Rishindra M. Reddy, Mark B. Orringer, Andrew C. Chang, Zhixiong Yang, David G. Beer, Guoan Chen The American Association for Cancer Research (AACR) 0008-5472 00085472 1538-7445 15387445 |
| shingle_catch_all_3 | Silencing of Long Noncoding RNA MIR22HG Triggers Cell Survival/Death Signaling via Oncogenes YBX1, MET, and p21 in Lung Cancer The long noncoding RNA (lncRNA) MIR22HG has previously been identified as a prognostic marker in hepatocellular carcinoma. Here, we performed a comprehensive analysis of lncRNA expression profiles from RNA-Seq data and report that MIR22HG plays a similar role in lung cancer. Analysis of 918 lung cancer and normal lung tissues and lung cancer cell lines revealed that MIR22HG was significantly downregulated in lung cancer; this decreased expression was associated with poor patient survival. MIR22HG bound and stabilized the YBX1 protein. Silencing of MIR22HG triggered both cell survival and cell death signaling through dysregulation of the oncogenes YBX1, MET, and p21. In this MIR22HG network, p21 played an oncogenic role by promoting cell proliferation and antiapoptosis in lung cancers. MIR22HG played a tumor-suppressive role as indicated by inhibition of multiple cell cycle–related genes in human primary lung tumors. These data show that MIR22HG has potential as a new diagnostic and prognostic marker and as a therapeutic target for lung cancer.Significance: The lncRNA MIR22HG functions as a tumor suppressor, with potential use a diagnostic/prognostic marker and therapeutic target in lung cancer. Cancer Res; 78(12); 3207–19. ©2018 AACR. Wenmei Su, Shumei Feng, Xiuyuan Chen, Xia Yang, Rui Mao, Chunfang Guo, Zhuwen Wang, Dafydd G. Thomas, Jules Lin, Rishindra M. Reddy, Mark B. Orringer, Andrew C. Chang, Zhixiong Yang, David G. Beer, Guoan Chen The American Association for Cancer Research (AACR) 0008-5472 00085472 1538-7445 15387445 |
| shingle_catch_all_4 | Silencing of Long Noncoding RNA MIR22HG Triggers Cell Survival/Death Signaling via Oncogenes YBX1, MET, and p21 in Lung Cancer The long noncoding RNA (lncRNA) MIR22HG has previously been identified as a prognostic marker in hepatocellular carcinoma. Here, we performed a comprehensive analysis of lncRNA expression profiles from RNA-Seq data and report that MIR22HG plays a similar role in lung cancer. Analysis of 918 lung cancer and normal lung tissues and lung cancer cell lines revealed that MIR22HG was significantly downregulated in lung cancer; this decreased expression was associated with poor patient survival. MIR22HG bound and stabilized the YBX1 protein. Silencing of MIR22HG triggered both cell survival and cell death signaling through dysregulation of the oncogenes YBX1, MET, and p21. In this MIR22HG network, p21 played an oncogenic role by promoting cell proliferation and antiapoptosis in lung cancers. MIR22HG played a tumor-suppressive role as indicated by inhibition of multiple cell cycle–related genes in human primary lung tumors. These data show that MIR22HG has potential as a new diagnostic and prognostic marker and as a therapeutic target for lung cancer.Significance: The lncRNA MIR22HG functions as a tumor suppressor, with potential use a diagnostic/prognostic marker and therapeutic target in lung cancer. Cancer Res; 78(12); 3207–19. ©2018 AACR. Wenmei Su, Shumei Feng, Xiuyuan Chen, Xia Yang, Rui Mao, Chunfang Guo, Zhuwen Wang, Dafydd G. Thomas, Jules Lin, Rishindra M. Reddy, Mark B. Orringer, Andrew C. Chang, Zhixiong Yang, David G. Beer, Guoan Chen The American Association for Cancer Research (AACR) 0008-5472 00085472 1538-7445 15387445 |
| shingle_title_1 | Silencing of Long Noncoding RNA MIR22HG Triggers Cell Survival/Death Signaling via Oncogenes YBX1, MET, and p21 in Lung Cancer |
| shingle_title_2 | Silencing of Long Noncoding RNA MIR22HG Triggers Cell Survival/Death Signaling via Oncogenes YBX1, MET, and p21 in Lung Cancer |
| shingle_title_3 | Silencing of Long Noncoding RNA MIR22HG Triggers Cell Survival/Death Signaling via Oncogenes YBX1, MET, and p21 in Lung Cancer |
| shingle_title_4 | Silencing of Long Noncoding RNA MIR22HG Triggers Cell Survival/Death Signaling via Oncogenes YBX1, MET, and p21 in Lung Cancer |
| timestamp | 2025-06-30T23:35:35.060Z |
| titel | Silencing of Long Noncoding RNA MIR22HG Triggers Cell Survival/Death Signaling via Oncogenes YBX1, MET, and p21 in Lung Cancer |
| titel_suche | Silencing of Long Noncoding RNA MIR22HG Triggers Cell Survival/Death Signaling via Oncogenes YBX1, MET, and p21 in Lung Cancer |
| topic | WW-YZ |
| uid | ipn_articles_6284360 |